PiepoliMFCorraUDendalePet al.Challenges in secondary prevention after acute myocardial infarction: A call for action. Eur Heart J Acute Cardiovasc Care2017; 6: 299–310.
2.
JernbergTHasvoldPHenrikssonMet al.Cardiovascular risk in post-myocardial infarction patients: Nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J2015; 36: 1163–1170.
3.
KotsevaKWoodDDe BacquerDet al.EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol2016; 23: 636–648.
4.
ZhaoQZhuYXuZet al.Effect of ticagrelor plus aspirin, ticagrelor alone, or aspirin alone on saphenous vein graft patency 1 year after coronary artery bypass grafting: A randomized clinical trial. JAMA2018; 319: 1677–1686.
5.
SchieleFEcarnotFChopardR. Coronary artery disease: Risk stratification and patient selection for more aggressive secondary prevention. Eur J Prev Cardiol2017; 24: 88–100.
6.
MannacioVADi TommasoLAntignanAet al.Aspirin plus clopidogrel for optimal platelet inhibition following off-pump coronary artery bypass surgery: Results from the CRYSSA (prevention of Coronary arteRY bypaSS occlusion After off-pump procedures) randomised study. Heart2012; 98: 1710–1715.
7.
Slim AM, Fentanes E, Thomas DM, et al. ASpirin and Plavix following Coronary Artery Bypass Grafting (ASAP-CABG): A randomized, double-blind, placebo-controlled pilot trial. BJMMR 2016; 14: 1–10.
8.
KulikALe MayMRVoisinePet al.Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: The Clopidogrel After Surgery for Coronary Artery Disease (CASCADE) trial. Circulation2010; 122: 2680–2687.
9.
SawJWongGCMayoJet al.Ticagrelor and aspirin for the prevention of cardiovascular events after coronary artery bypass graft surgery. Heart2016; 102: 763–769.
10.
AgarwalNMahmoudANPatelNKet al.Meta-analysis of aspirin versus dual antiplatelet therapy following coronary artery bypass grafting. Am J Cardiol2018; 121: 32–40.
